• Nine abstracts ready for the SfN conference in November.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent

Bite Size Bulletins

Follow us on Linkedin and Twitter. Transpharmation's CEO, Mark Duxon, along with many of his team members are active on LinkedIn and we regularly post about new studies, collaborations, innovative poster publications and much more besides. Please see our team page to see who you'd like to be connected to and you will be amongst the first to have news delivered straight to your LinkedIn news feed and be able to direct your conversation with the most suitable person.

Follow Transpharmation on LinkedIn and Twitter to keep up with all the latest news.linkedintwitter




Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design